Home Nephro News Practical management of C3 glomerulopathy and immunoglobulin-mediated MPGN: facts and uncertainties.

Practical management of C3 glomerulopathy and immunoglobulin-mediated MPGN: facts and uncertainties.

Credits to the Source Link Obum
Practical management of C3 glomerulopathy and immunoglobulin-mediated MPGN: facts and uncertainties.
    • Fakhouri F.
    • Fremeaux-Bacchi V.
    • Noel L.H.
    • Cook H.T.
    • Pickering M.C.

    C3 glomerulopathy: a new classification.

    Nat Rev Nephrol. 2010; 6: 494-499

  • Membranoproliferative glomerulonephritis–a new look at an old entity.

    N Engl J Med. 2012; 366: 1119-1131

    • Servais A.
    • Noel L.H.
    • Roumenina L.T.
    • et al.

    Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies.

    Kidney Int. 2012; 82: 454-464

    • Sethi S.
    • Fervenza F.C.
    • Zhang Y.
    • et al.

    C3 glomerulonephritis: clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up.

    Kidney Int. 2012; 82: 465-473

    • Iatropoulos P.
    • Daina E.
    • Curreri M.
    • et al.

    Cluster Analysis Identifies Distinct Pathogenetic Patterns in C3 Glomerulopathies/Immune Complex-Mediated Membranoproliferative GN.

    J Am Soc Nephrol. 2018; 29: 283-294

    • Le Quintrec M.
    • Lapeyraque A.L.
    • Lionet A.
    • et al.

    Patterns of Clinical Response to Eculizumab in Patients With C3 Glomerulopathy.

    Am J Kidney Dis. 2018; 72: 84-92

    • Rabasco C.
    • Cavero T.
    • Roman E.
    • et al.

    Effectiveness of mycophenolate mofetil in C3 glomerulonephritis.

    Kidney Int. 2015; 88: 1153-1160

    • Avasare R.S.
    • Canetta P.A.
    • Bomback A.S.
    • et al.

    Mycophenolate Mofetil in Combination with Steroids for Treatment of C3 Glomerulopathy: A Case Series.

    Clin J Am Soc Nephrol. 2018; 13: 406-413

    • Ruggenenti P.
    • Daina E.
    • Gennarini A.
    • et al.

    C5 Convertase Blockade in Membranoproliferative Glomerulonephritis: A Single-Arm Clinical Trial.

    Am J Kidney Dis. 2019; 74: 224-238

    • Fakhouri F.
    • Zuber J.
    • Fremeaux-Bacchi V.
    • Loirat C.

    Haemolytic uraemic syndrome.

    Lancet. 2017;

    • Fakhouri F.
    • Fremeaux-Bacchi V.

    Does hemolytic uremic syndrome differ from thrombotic thrombocytopenic purpura?.

    Nat Clin Pract Nephrol. 2007; 3: 679-687

    • Fremeaux-Bacchi V.
    • Fakhouri F.
    • Garnier A.
    • et al.

    Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults.

    Clin J Am Soc Nephrol. 2013; 8: 554-562

    • Noris M.
    • Caprioli J.
    • Bresin E.
    • et al.

    Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype.

    Clin J Am Soc Nephrol. 2010; 5: 1844-1859

    • Goodship T.H.
    • Cook H.T.
    • Fakhouri F.
    • et al.

    Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference.

    Kidney Int. 2017; 91: 539-551

    • de Jorge E.G.
    • Macor P.
    • Paixao-Cavalcante D.
    • et al.

    The development of atypical hemolytic uremic syndrome depends on complement C5.

    J Am Soc Nephrol. 2011; 22: 137-145

    • Smith-Jackson K.
    • Yang Y.
    • Denton H.
    • et al.

    Hyperfunctional complement C3 promotes C5-dependent atypical hemolytic uremic syndrome in mice.

    J Clin Invest. 2019; 129: 1061-1075

    • Legendre C.M.
    • Licht C.
    • Muus P.
    • et al.

    Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome.

    N Engl J Med. 2013; 368: 2169-2181

    • Fakhouri F.
    • Hourmant M.
    • Campistol J.M.
    • et al.

    Terminal Complement Inhibitor Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome: A Single-Arm, Open-Label Trial.

    Am J Kidney Dis. 2016; 68: 84-93

    • Azukaitis K.
    • Simkova E.
    • Majid M.A.
    • et al.

    The Phenotypic Spectrum of Nephropathies Associated with Mutations in Diacylglycerol Kinase epsilon.

    J Am Soc Nephrol. 2017; 28: 3066-3075

    • Nasr S.H.
    • Valeri A.M.
    • Appel G.B.
    • et al.

    Dense deposit disease: clinicopathologic study of 32 pediatric and adult patients.

    Clin J Am Soc Nephrol. 2009; 4: 22-32

    • Walker P.D.
    • Ferrario F.
    • Joh K.
    • Bonsib S.M.

    Dense deposit disease is not a membranoproliferative glomerulonephritis.

    Mod Pathol. 2007; 20: 605-616

    • Sethi S.
    • Gamez J.D.
    • Vrana J.A.
    • et al.

    Glomeruli of Dense Deposit Disease contain components of the alternative and terminal complement pathway.

    Kidney Int. 2009; 75: 952-960

    • Sethi S.
    • Vrana J.A.
    • Fervenza F.C.
    • et al.

    Characterization of C3 in C3 glomerulopathy.

    Nephrol Dial Transplant. 2017; 32: 459-465

    • Rose K.L.
    • Paixao-Cavalcante D.
    • Fish J.
    • et al.

    Factor I is required for the development of membranoproliferative glomerulonephritis in factor H-deficient mice.

    J Clin Invest. 2008; 118: 608-618

    • Fakhouri F.
    • de Jorge E.G.
    • Brune F.
    • Azam P.
    • Cook H.T.
    • Pickering M.C.

    Treatment with human complement factor H rapidly reverses renal complement deposition in factor H-deficient mice.

    Kidney Int. 2010; 78: 279-286

    • Droz D.
    • Zanetti M.
    • Noel L.H.
    • Leibowitch J.

    Dense deposits disease.

    Nephron. 1977; 19: 1-11

    • Bomback A.S.
    • Santoriello D.
    • Avasare R.S.
    • et al.

    C3 glomerulonephritis and dense deposit disease share a similar disease course in a large United States cohort of patients with C3 glomerulopathy.

    Kidney Int. 2018; 93: 977-985

    • Medjeral-Thomas N.R.
    • O’Shaughnessy M.M.
    • O’Regan J.A.
    • et al.

    C3 glomerulopathy: clinicopathologic features and predictors of outcome.

    Clin J Am Soc Nephrol. 2014; 9: 46-53

    • Servais A.
    • Fremeaux-Bacchi V.
    • Lequintrec M.
    • et al.

    Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome.

    J Med Genet. 2007; 44: 193-199

    • Hou J.
    • Markowitz G.S.
    • Bomback A.S.
    • et al.

    Toward a working definition of C3 glomerulopathy by immunofluorescence.

    Kidney Int. 2014; 85: 450-456

    • Levine A.P.
    • Chan M.M.Y.
    • Sadeghi-Alavijeh O.
    • et al.

    Large-Scale Whole-Genome Sequencing Reveals the Genetic Architecture of Primary Membranoproliferative GN and C3 Glomerulopathy.

    J Am Soc Nephrol. 2020;

    • Kerns E.
    • Rozansky D.
    • Troxell M.L.

    Evolution of immunoglobulin deposition in C3-dominant membranoproliferative glomerulopathy.

    Pediatr Nephrol. 2013; 28: 2227-2231

    • Sethi S.
    • Nasr S.H.
    • De Vriese A.S.
    • Fervenza F.C.

    C4d as a Diagnostic Tool in Proliferative GN.

    J Am Soc Nephrol. 2015; 26: 2852-2859

    • Singh G.
    • Singh S.K.
    • Nalwa A.
    • et al.

    Glomerular C4d Staining Does Not Exclude a C3 Glomerulopathy.

    Kidney Int Rep. 2019; 4: 698-709

    • Fremeaux-Bacchi V.
    • Weiss L.
    • Demouchy C.
    • May A.
    • Palomera S.
    • Kazatchkine M.D.

    Hypocomplementaemia of poststreptococcal acute glomerulonephritis is associated with C3 nephritic factor (C3NeF) IgG autoantibody activity.

    Nephrol Dial Transplant. 1994; 9: 1747-1750

    • Chauvet S.
    • Berthaud R.
    • Devriese M.
    • et al.

    Anti-Factor B Antibodies and Acute Postinfectious GN in Children.

    J Am Soc Nephrol. 2020;

    • Pickering M.C.
    • D’Agati V.D.
    • Nester C.M.
    • et al.

    C3 glomerulopathy: consensus report.

    Kidney Int. 2013;

    • Vernon K.A.
    • Goicoechea de Jorge E.
    • Hall A.E.
    • et al.

    Acute presentation and persistent glomerulonephritis following streptococcal infection in a patient with heterozygous complement factor H-related protein 5 deficiency.

    Am J Kidney Dis. 2012; 60: 121-125

    • Oosterveld M.J.
    • Garrelfs M.R.
    • Hoppe B.
    • et al.

    Eculizumab in Pediatric Dense Deposit Disease.

    Clin J Am Soc Nephrol. 2015; 10: 1773-1782

    • Marinozzi M.C.
    • Chauvet S.
    • Le Quintrec M.
    • et al.

    C5 nephritic factors drive the biological phenotype of C3 glomerulopathies.

    Kidney Int. 2017; 92: 1232-1241

    • Zhang Y.
    • Meyer N.C.
    • Fervenza F.C.
    • et al.

    C4 Nephritic Factors in C3 Glomerulopathy: A Case Series.

    Am J Kidney Dis. 2017; 70: 834-843

    • Ravindran A.
    • Fervenza F.C.
    • Smith R.J.H.
    • Sethi S.

    C3 glomerulopathy associated with monoclonal Ig is a distinct subtype.

    Kidney Int. 2018; 94: 178-186

    • Corvillo F.
    • Bravo Garcia-Morato M.
    • Nozal P.
    • et al.

    Serum properdin consumption as a biomarker of C5 convertase dysregulation in C3 glomerulopathy.

    Clin Exp Immunol. 2016; 184: 118-125

    • Marinozzi M.C.
    • Roumenina L.T.
    • Chauvet S.
    • et al.

    Anti-Factor B and Anti-C3b Autoantibodies in C3 Glomerulopathy and Ig-Associated Membranoproliferative GN.

    J Am Soc Nephrol. 2017; 28: 1603-1613

    • Blanc C.
    • Togarsimalemath S.K.
    • Chauvet S.
    • et al.

    Anti-factor H autoantibodies in C3 glomerulopathies and in atypical hemolytic uremic syndrome: one target, two diseases.

    J Immunol. 2015; 194: 5129-5138

  • Nicolas C, Vuiblet V, Baudouin V, et al. C3 nephritic factor associated with C3 glomerulopathy in children. Pediatr Nephrol.

    • Bu F.
    • Borsa N.G.
    • Jones M.B.
    • et al.

    High-Throughput Genetic Testing for Thrombotic Microangiopathies and C3 Glomerulopathies.

    J Am Soc Nephrol. 2016; 27: 1245-1253

    • Zipfel P.F.
    • Wiech T.
    • Stea E.D.
    • Skerka C.

    CFHR Gene Variations Provide Insights in the Pathogenesis of the Kidney Diseases Atypical Hemolytic Uremic Syndrome and C3 Glomerulopathy.

    J Am Soc Nephrol. 2020; 31: 241-256

    • Gale D.P.
    • de Jorge E.G.
    • Cook H.T.
    • et al.

    Identification of a mutation in complement factor H-related protein 5 in patients of Cypriot origin with glomerulonephritis.

    Lancet. 2010; 376: 794-801

    • Goodship T.H.
    • Cook H.T.
    • Fakhouri F.
    • et al.

    Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference.

    Kidney Int. 2016;

    • Wilson H.R.
    • Medjeral-Thomas N.R.
    • Gilmore A.C.
    • et al.

    Glomerular membrane attack complex is not a reliable marker of ongoing C5 activation in lupus nephritis.

    Kidney Int. 2019; 95: 655-665

    • Chauvet S.
    • Fremeaux-Bacchi V.
    • Petitprez F.
    • et al.

    Treatment of B-cell disorder improves renal outcome of patients with monoclonal gammopathy-associated C3 glomerulopathy.

    Blood. 2016; 129: 1437-1447

    • Jokiranta T.S.
    • Solomon A.
    • Pangburn M.K.
    • Zipfel P.F.
    • Meri S.

    Nephritogenic lambda light chain dimer: a unique human miniautoantibody against complement factor H.

    J Immunol. 1999; 163: 4590-4596

    • Chauvet S.
    • Roumenina L.T.
    • Aucouturier P.
    • et al.

    Both Monoclonal and Polyclonal Immunoglobulin Contingents Mediate Complement Activation in Monoclonal Gammopathy Associated-C3 Glomerulopathy.

    Front Immunol. 2018; 9: 2260

    • Jayne D.R.W.
    • Bruchfeld A.N.
    • Harper L.
    • et al.

    Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis.

    J Am Soc Nephrol. 2017; 28: 2756-2767

    • Lesher A.M.
    • Zhou L.
    • Kimura Y.
    • et al.

    Combination of factor H mutation and properdin deficiency causes severe C3 glomerulonephritis.

    J Am Soc Nephrol. 2013; 24: 53-65

    • Ruseva M.M.
    • Vernon K.A.
    • Lesher A.M.
    • et al.

    Loss of properdin exacerbates C3 glomerulopathy resulting from factor H deficiency.

    J Am Soc Nephrol. 2013; 24: 43-52

    • Slade C.
    • Bosco J.
    • Unglik G.
    • Bleasel K.
    • Nagel M.
    • Winship I.

    Deficiency in complement factor B.

    N Engl J Med. 2013; 369: 1667-1669

    • Biesma D.H.
    • Hannema A.J.
    • van Velzen-Blad H.
    • et al.

    A family with complement factor D deficiency.

    J Clin Invest. 2001; 108: 233-240

    • Schejbel L.
    • Fadnes D.
    • Permin H.
    • Lappegard K.T.
    • Garred P.
    • Mollnes T.E.

    Primary complement C5 deficiencies – molecular characterization and clinical review of two families.

    Immunobiology. 2013; 218: 1304-1310

    • Wilson G.J.
    • Cho Y.
    • Teixiera-Pinto A.
    • et al.

    Long-term outcomes of patients with end-stage kidney disease due to membranoproliferative glomerulonephritis: an ANZDATA registry study.

    BMC Nephrol. 2019; 20: 417

    • O’Shaughnessy M.M.
    • Liu S.
    • Montez-Rath M.E.
    • Lafayette R.A.
    • Winkelmayer W.C.

    Kidney Transplantation Rates Across Glomerulonephritis Subtypes in the United States.

    Transplantation. 2017; 101: 2636-2647

    • Regunathan-Shenk R.
    • Avasare R.S.
    • Ahn W.
    • et al.

    Kidney Transplantation in C3 Glomerulopathy: A Case Series.

    Am J Kidney Dis. 2019; 73: 316-323

    • Zand L.
    • Lorenz E.C.
    • Cosio F.G.
    • et al.

    Clinical findings, pathology, and outcomes of C3GN after kidney transplantation.

    J Am Soc Nephrol. 2014; 25: 1110-1117

    • Alasfar S.
    • Carter-Monroe N.
    • Rosenberg A.Z.
    • Montgomery R.A.
    • Alachkar N.

    Membranoproliferative glomerulonephritis recurrence after kidney transplantation: using the new classification.

    BMC Nephrol. 2016; 17: 7

    • Pippias M.
    • Stel V.S.
    • Areste-Fosalba N.
    • et al.

    Long-term Kidney Transplant Outcomes in Primary Glomerulonephritis: Analysis From the ERA-EDTA Registry.

    Transplantation. 2016; 100: 1955-1962

    • Pruthi R.
    • McClure M.
    • Casula A.
    • et al.

    Long-term graft outcomes and patient survival are lower posttransplant in patients with a primary renal diagnosis of glomerulonephritis.

    Kidney Int. 2016; 89: 918-926

    • Moroni G.
    • Casati C.
    • Quaglini S.
    • et al.

    Membranoproliferative glomerulonephritis type I in renal transplantation patients: a single-center study of a cohort of 68 renal transplants followed up for 11 years.

    Transplantation. 2011; 91: 1233-1239

    • Duineveld C.
    • Verhave J.C.
    • Berger S.P.
    • van de Kar N.
    • Wetzels J.F.M.

    Living Donor Kidney Transplantation in Atypical Hemolytic Uremic Syndrome: A Case Series.

    Am J Kidney Dis. 2017; 70: 770-777

    • Zuber J.
    • Frimat M.
    • Caillard S.
    • et al.

    Use of Highly Individualized Complement Blockade Has Revolutionized Clinical Outcomes after Kidney Transplantation and Renal Epidemiology of Atypical Hemolytic Uremic Syndrome.

    J Am Soc Nephrol. 2019; 30: 2449-2463

    • Little M.A.
    • Dupont P.
    • Campbell E.
    • Dorman A.
    • Walshe J.J.

    Severity of primary MPGN, rather than MPGN type, determines renal survival and post-transplantation recurrence risk.

    Kidney Int. 2006; 69: 504-511

  • Source Link

    Related Posts

    Leave a Comment

    This website uses cookies to improve your experience. We will assume you are ok with this, but you can opt-out if you wish. Accept Read More

    %d bloggers like this: